Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338039 · ClinicalTrials.gov registry record · Phase 2
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT00338039: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00338039 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00338039, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the efficacy of a combination of cetuximab with systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. The primary endpoint is actuarial one-year survival. The secondary objectives are: * To evaluate the local tumor response in patients treated with the above regimen. * To characterize the safety of the above regimen.
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- RADIATION Radiotherapy
- DRUG Cetuximab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338039
The ClinicalTrials.gov registry entry for NCT00338039 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT00338039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338039 about?
NCT00338039 is a clinical study titled "Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients". The primary objective is to evaluate the efficacy of a combination of cetuximab with systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. The primary endpoint is actuarial one-year survival. The secondary objectives are: * To evaluate the local tumor response in ...
What is the current status of trial NCT00338039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2005-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00338039?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Radiotherapy (RADIATION), Cetuximab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00338039?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.